Omeros Corporation
The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000
https://www.omeros.com
版塊: Healthcare
行業: Biotechnology
全職員工: 198
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President | 1.79M | 無 | 1959 |
| Mr. Michael A. Jacobsen | Chief Accounting Officer, VP of Finance & Treasurer | 518.6k | 無 | 1958 |
| Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary | 503.24k | 無 | 1979 |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder | 無 | 無 | 1963 |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science | 無 | 無 | 1957 |
| Mr. Peter W. Williams | Vice President of Human Resources | 無 | 無 | 1968 |
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems | 無 | 無 | 1959 |
| Ms. Nadia Dac | VP & Chief Commercial Officer | 無 | 無 | 1970 |
| Dr. Andreas Grauer M.D. | VP & Chief Medical Officer | 無 | 無 | 1961 |
描述
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
公司管治
截至 2024年5月1日 止，Omeros Corporation 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：8；董事會：9；股東權利：5；現金賠償：8。
